New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States.

Résumé fourni par la source

Prescriptions made for GLP-1 agonists under various brand names (e.g., Ozempic, Wegovy) have more than tripled since 2020. However, research on their use and their side effects at the population level is in its infancy. This study presents descriptive findings from a 2025 survey fielded to a nationally representative sample of U.S. adults as part of RAND's American Life Panel that show prevalence rates of GLP-1 agonist use and side effects.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.